Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million
Zydus Lifesciences' subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Nasdaq-listed Assertio Holdings for approximately USD 166.4 million at USD 23.50 per share in cash. The deal strengthens Zydus's U.S. specialty oncology presence through Assertio's primary asset ROLVEDON®, which recorded USD 68.23 million in turnover in 2025, and its 170+ community oncology accounts. The transaction, expected to close in FY2026-27, will result in Assertio being delisted from Nasdaq.
*this image is generated using AI for illustrative purposes only.
Zydus Lifesciences Limited announced that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc., a Nasdaq-listed U.S. specialty pharmaceutical company. The acquisition is being executed through Zydus Worldwide's wholly owned acquisition subsidiary, Zara Merger Sub Inc. The transaction is valued at USD 23.50 per share in cash, representing a total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method. The deal has been approved by the Boards of Directors of both Zydus Worldwide and Assertio.
Transaction Structure and Key Terms
The following table summarises the key parameters of the proposed acquisition:
| Parameter: | Details |
|---|---|
| Acquirer: | Zydus Worldwide DMCC (subsidiary of Zydus Lifesciences Limited), through Zara Merger Sub Inc. |
| Target: | Assertio Holdings, Inc. |
| Consideration Type: | All-cash |
| Price Per Share: | USD 23.50 |
| Total Consideration: | Approximately USD 166.4 million (fully-diluted basis, treasury stock method) |
| Shareholding Acquired: | 100% of outstanding shares |
| Transaction Structure: | Tender offer followed by merger |
| Expected Completion: | Financial year 2026-27 |
| Post-Completion Status: | Assertio to be delisted from Nasdaq |
The transaction is structured as a tender offer to be followed by a merger, pursuant to which Zara Merger Sub Inc. will merge with and into Assertio, with Assertio continuing as the surviving corporation. The tender offer is expected to commence within five business days following the date of the merger agreement. The proposed acquisition does not fall within related party transactions, and none of the promoter, promoter group, or group companies have any interest in the proposed acquisition.
About Assertio Holdings and Its Key Asset
Assertio is a U.S.-based specialty pharmaceutical company headquartered in Lake Forest, Illinois, with established commercial capabilities for marketing and distribution of differentiated products. Its primary asset is ROLVEDON® (eflapegrastim-xnst), approved as a BLA by the USFDA as a long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive care market. On April 8, 2026, Assertio completed the sale of certain other products to Cosette Pharmaceuticals Inc. The adjusted turnover for ROLVEDON® — the surviving product — for the past three calendar years is as follows:
| Calendar Year: | Turnover (USD million) |
|---|---|
| 2025 | 68.23 |
| 2024 | 60.09 |
| 2023 (Note 1) | 18.18 |
Note 1: ROLVEDON® was acquired by Assertio on July 31, 2023; the turnover for CY 2023 is for a period of 5 months.
Strategic Rationale
The proposed acquisition is in line with Zydus's strategic objective of building a specialty oncology company in the U.S. Assertio's commercial infrastructure offers several key advantages:
- 170+ community oncology accounts providing an established market presence
- Buy-and-bill infrastructure offering a ready-made base to build a broader oncology platform
- An approved oncology asset in ROLVEDON® with a growing revenue trajectory
- An immediate U.S. specialty oncology commercial footprint to support portfolio expansion
Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited, stated: "This transaction represents a strategic step in strengthening our specialty and oncology footprint in the U.S. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally."
Advisors and Regulatory Requirements
The transaction is subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock, as well as requisite regulatory approvals. Paul Weiss, Rifkind, Wharton & Garrison LLP is serving as legal counsel to Zydus. Moelis & Company LLC is serving as financial advisor to Assertio, and Gibson, Dunn & Crutcher LLP is serving as its legal counsel. Upon successful completion of the transaction, Assertio will be delisted from Nasdaq.
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.58% | +5.63% | +7.51% | +5.04% | +9.96% | +60.69% |
How might Zydus leverage Assertio's 170+ community oncology accounts to accelerate the commercialization of its own oncology pipeline products in the U.S. market?
Could ROLVEDON®'s growing revenue trajectory face competitive pressure from biosimilar entrants, and how might this impact Zydus's return on its $166.4 million investment?
What additional oncology assets or acquisitions might Zydus pursue to build out its U.S. specialty oncology platform beyond ROLVEDON® following this deal's completion?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
